US Pharmaceutical Development Pipeline

Epidiolex® (cannabidiol)
Dravet Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Lennox-Gastaut Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Tuberous Sclerosis Complex
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Rett Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Sativex® (nabiximols)
MS Spasticity
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Neuropathic pain/Other neuro symptoms
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
CBDV (GWP42006)
Epilepsy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Autism Spectrum Disorders
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Rett Syndrome
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Other (GWP42002 / GWP42003)
GLIOBLASTOMA
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Schizophrenia
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 
Neonatal Hypoxic-Ischemic Encephalopathy
Pre-Clinic 
Phase 1 
Phase 2 
Phase 3 
Submit 
Approved 

Epidiolex® is an investigational product outside of the United States. Sativex® is not approved in the United States for any indication; it is approved for MS Spasticity in certain countries outside of the United States. All other products mentioned are investigational only. See www.gwpharm.com for full details.

Medical Information

If you are a healthcare professional interested in additional scientific and clinical information on Greenwich Biosciences products, EPIDIOLEX, and cannabinoids, or would like to submit a medical request form

Visit Medical Information >

EPIDIOLEX CLINICAL TRIALS

For the most up-to-date list of publicly and privately supported clinical studies of human participants treated with EPIDIOLEX

VISIT ClinicalTrials.gov >